In adults with episodic migraine and inadequate response to 2-4 oral preventive classes, rimegepant 75 mg every other day cut monthly migraine days more than placebo over 12 weeks (-2.1 vs -0.5; difference -1.6 days); tolerability was similar to placebo.
RCTn = 652
Pozo-Rosich et al. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications